GAVASSO, SABRINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.474
AS - Asia 4.116
EU - Europa 1.818
AF - Africa 633
SA - Sud America 627
OC - Oceania 65
Continente sconosciuto - Info sul continente non disponibili 37
Totale 15.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.097
SG - Singapore 1.286
CN - Cina 721
VN - Vietnam 587
HK - Hong Kong 438
BR - Brasile 378
IT - Italia 367
BD - Bangladesh 174
FI - Finlandia 170
DE - Germania 151
FR - Francia 140
IN - India 129
NL - Olanda 107
SE - Svezia 98
GB - Regno Unito 92
PL - Polonia 83
IQ - Iraq 63
CA - Canada 60
RU - Federazione Russa 58
TR - Turchia 52
PH - Filippine 50
UA - Ucraina 46
ES - Italia 45
MX - Messico 44
ZA - Sudafrica 44
PK - Pakistan 43
JP - Giappone 42
AR - Argentina 38
AT - Austria 38
SA - Arabia Saudita 38
ID - Indonesia 35
CO - Colombia 32
EC - Ecuador 32
AE - Emirati Arabi Uniti 31
IE - Irlanda 30
MY - Malesia 30
EG - Egitto 29
VE - Venezuela 28
PY - Paraguay 27
AZ - Azerbaigian 25
CL - Cile 25
LB - Libano 24
CZ - Repubblica Ceca 23
DO - Repubblica Dominicana 23
ET - Etiopia 23
KE - Kenya 23
PE - Perù 23
GR - Grecia 22
TW - Taiwan 22
BJ - Benin 21
JO - Giordania 21
NI - Nicaragua 21
RO - Romania 21
BG - Bulgaria 20
HN - Honduras 20
KG - Kirghizistan 20
KR - Corea 20
MN - Mongolia 20
PA - Panama 20
TH - Thailandia 20
UZ - Uzbekistan 20
BF - Burkina Faso 19
CI - Costa d'Avorio 19
CY - Cipro 19
JM - Giamaica 19
ML - Mali 19
NP - Nepal 19
CW - ???statistics.table.value.countryCode.CW??? 18
KH - Cambogia 18
ME - Montenegro 18
CD - Congo 17
CG - Congo 17
CR - Costa Rica 17
DZ - Algeria 17
HR - Croazia 17
IL - Israele 17
LA - Repubblica Popolare Democratica del Laos 17
SD - Sudan 17
SN - Senegal 17
UY - Uruguay 17
AU - Australia 16
BE - Belgio 16
CH - Svizzera 16
EE - Estonia 16
GH - Ghana 16
LV - Lettonia 16
LY - Libia 16
MA - Marocco 16
MD - Moldavia 16
MU - Mauritius 16
MZ - Mozambico 16
RS - Serbia 16
TN - Tunisia 16
GA - Gabon 15
GE - Georgia 15
MG - Madagascar 15
MW - Malawi 15
NO - Norvegia 15
PT - Portogallo 15
TJ - Tagikistan 15
Totale 15.081
Salva come PNG Salva come JPEG
Città #
San Jose 931
Fairfield 925
Ashburn 850
Singapore 792
Woodbridge 551
Chandler 501
Hong Kong 383
Ann Arbor 375
Houston 375
Seattle 364
Cambridge 320
Wilmington 282
Ho Chi Minh City 192
Los Angeles 187
Beijing 173
Santa Clara 150
Hanoi 125
Chicago 121
Boardman 115
Jacksonville 109
Helsinki 97
San Diego 94
Princeton 83
New York 75
Lauterbourg 71
Des Moines 64
Medford 54
Padova 51
Buffalo 49
Salt Lake City 46
Council Bluffs 40
Munich 40
Roxbury 39
Bytom 36
Dallas 34
Orem 34
São Paulo 32
Villafranca Padovana 32
Dong Ket 31
Milan 31
Nanjing 29
Frankfurt am Main 27
London 27
Da Nang 26
Guangzhou 26
Tampa 26
Tokyo 26
Vienna 26
Warsaw 26
Montreal 25
Baku 24
Padua 24
Brooklyn 23
Dublin 23
Baghdad 22
Elk Grove Village 22
Johannesburg 22
Amsterdam 21
Chennai 21
Nairobi 21
Shenyang 21
Addis Ababa 20
Cotonou 20
Tashkent 20
Ulan Bator 20
Managua 19
Abidjan 18
Amman 18
Atlanta 18
Bamako 18
Panama City 18
Rio de Janeiro 18
Stockholm 18
Dakar 17
Hefei 17
Ouagadougou 17
Rome 17
Denver 16
Phnom Penh 16
Shanghai 16
Willemstad 16
Antananarivo 15
Bishkek 15
Dushanbe 15
Falls Church 15
Haiphong 15
Hebei 15
Kuala Lumpur 15
Montevideo 15
Riyadh 15
Andorra la Vella 14
Havana 14
Kinshasa 14
Libreville 14
Lusaka 14
Nuremberg 14
Podgorica 14
Quito 14
San José 14
Vientiane 14
Totale 9.994
Salva come PNG Salva come JPEG
Nome #
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection 350
Dynamics of circulating microparticles in obesity after weight loss 336
Endothelial damage of the portal vein is associated with Heparin-like effect in advanced stages of cirrhosis 299
Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study 298
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 286
In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context 272
Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease 267
Effects of long-term administration of recombinant human protein C in xenografted primates. 264
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 251
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features 250
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study 248
Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation 245
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure 241
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 238
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 238
Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery 238
Peculiar laboratory phenotype/ genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism 235
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 227
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 225
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 221
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis 218
Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. 217
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 217
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? 215
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 214
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC 212
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 210
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis 209
Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! 208
Activation of the Contact System and Intrinsic Pathway in Peripheral and Portal Venous Circulations in Liver Cirrhosis 207
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 206
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. 206
Local prothrombotic state in portal venous system in cirrhosis 204
Platelet factor V levels in moderate to severe congenital factor V deficiency. 200
Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19 200
The haemostatic system in acromegaly: a single-centre case–control study 197
Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis" 196
Factor VIIa-antithrombin complexes in children with ischemic stroke. 194
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 191
“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate 190
Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis 189
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 189
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. 189
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death 188
Whole blood thrombin generation shows a significant hypo-coagulable state in patients with decompensated cirrhosis 187
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 187
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. 186
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis 185
Coagulation factor XI in cirrhosis does not predict thrombo-hemorrhagic complications and hepatic decompensation 184
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 181
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. 181
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 180
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections 179
Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. 178
Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome 178
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 175
Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. 173
Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis 171
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 171
Effect on thrombin generation of the "in vitro" addition of low-dose LMWH to plasma of healthy pregnant and nonpregnant women. 169
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 167
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. 163
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 163
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). 163
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants 161
Role of local endothelial alterations in the pathogenesis of portal vein thrombosis in cirrhosis 161
Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. 160
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. 159
Similar hypercoagulable state and thrombosis risk in type Iand type III protein S-deficient individuals from families with mixed type I/IIIprotein S deficiency. 158
Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. 148
Circulating microparticles in carriers of prothrombin G20210A mutation. 147
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. 146
Thrombosis and thrombophilia in children: a systematic review. 146
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. 144
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. 143
Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. 139
null 122
Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous). 105
Recompensation after acute decompensation in alcohol-related cirrhosis is rare and likely unrelated to platelet-poor plasma thrombin generation and fibrinolysis 87
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. 80
Antiphosphatidylserine/prothrombin antibodies define a high-risk antiphospholipid syndrome profile associated with organ damage 40
Totale 15.862
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.208
article - articoli 44.131
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.339
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.122 56 108 159 36 53 106 57 98 62 44 109 234
2022/2023857 168 114 49 96 139 103 5 50 85 4 39 5
2023/2024379 16 70 45 48 22 45 19 10 13 20 29 42
2024/20251.887 3 124 100 64 236 60 120 149 159 76 298 498
2025/20268.154 352 582 893 1.253 906 382 1.275 594 917 407 349 244
2026/202798 98 0 0 0 0 0 0 0 0 0 0 0
Totale 15.862